Dr. J Colombo PhD
“Life Vessel therapy can help patient’s ANS to normalize.”
Overall Life Vessel therapy can help patients’ ANSs to normalize. Once normal, the primary disease can be treated more aggressively. Follow-up reports from patients suggest that the long term effects of Life Vessel therapy can remain. Apparently, this is due to the plasticity of the ANS and its ability to “learn” or “be re-trained”. Once re-trained, the ANS can carry forward in its new state without the need for further therapy. Proper ANS balance is associated with improved wellness and improved outcomes. Proper ANS balance, however does not immediately or always correct the end-organ dysfunction. End-organ dysfunction would be the reason for needing continued therapy or maintenance dosing to help maintain ANS balance once established.
Chronic disease leads to autonomic neuropathy. Autonomic neuropathy is associated with a five-fold increase in mortality. Autonomic dysfunction precedes autonomic neuropathy, but is asymptomatic, except in cases of dizziness and abnormal sweating. Therefore, the chronic disease itself is the indication for ANS testing. This point has been supported by the medical leadership (AAN, AHA,, ADA2,3,,, AAFP, JDIF2, and NIH2) and is supported by Medicare which encourages (reimburses) periodic testing to detect autonomic decline early to intervene prior to end-organ dysfunction or failure forces catastrophic conditions that require expensive procedures. Life Vessel therapy has been shown to normalize patients with long standing chronic disease. ANS monitoring shows that there is an autonomic effect associated with Life Vessel therapy which seems to help to contribute to the patients overall improvement in health.